Literature DB >> 10195778

Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses.

R J Mrsny1, A L Daugherty, C M Fryling, D J FitzGerald.   

Abstract

We have used a mouse immunization model to evaluate the potential for a chimera protein composed of a nontoxic form of Pseudomonas exotoxin (ntPE) to incite and sustain a mucosal immune response against an integrated antigen. The chimera, termed ntPE-V3MN26, contained 26 amino acids of the gp120 V3 loop region sequence of the MN strain of HIV-1 integrated in place of the Ib region of ntPE. Following either vaginal, rectal, oral or subcutaneous administration and boosting, anti-gp120-specific IgA and IgG levels in serum and saliva samples were assessed by ELISA. All dosing regimens stimulated significant and comparable salivary IgA and serum IgG responses at 1, 2 and 3 months after the initial inoculation. Following a boost at 16 months with ntPE-V3MN26, a strong memory response to the antigen was observed. Isotyping of serum antibodies at this time suggested that both a Thl and a Th2 response had been induced. Responses to ntPE-V3MN26 following subcutaneous injection in the presence or absence of Freund's adjuvant demonstrated that Freund's adjuvant resulted in a three-fold greater enhancement of immune response compared to administration of chimera alone. These results demonstrate that mucosal presentation of a chimera composed of a nontoxic form of Pseudomonas exotoxin can result in a strong mucosal and systemic antigen-specific immune response to an integrated antigen. The profound memory responses induced by this chimera may be particularly useful for practical vaccine applications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195778     DOI: 10.1016/s0264-410x(98)00380-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   4.169


  6 in total

1.  Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.

Authors:  Mari Ohmura; Masafumi Yamamoto; Chikako Tomiyama-Miyaji; Yoshikazu Yuki; Yoshifumi Takeda; Hiroshi Kiyono
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.

Authors:  R Hertle; R Mrsny; D J Fitzgerald
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.609

3.  Efficiency of recombinant bacille Calmette-Guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice.

Authors:  Young Jae Kim
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

4.  Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs.

Authors:  Sreerupa Challa; Steven M Szczepanek; Debra Rood; Roger W Barrette; Lawrence K Silbart
Journal:  Adv Virol       Date:  2011-09-22

5.  The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response.

Authors:  Tatiane Ferreira; Elizabeth De Gaspari
Journal:  ScientificWorldJournal       Date:  2012-04-01

6.  Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.

Authors:  Jennifer C Hsieh; Doris M Tham; Weijun Feng; Fan Huang; Selamawit Embaie; Keyi Liu; Deborah Dean; Ralf Hertle; David J Fitzgerald; Randall J Mrsny
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.609

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.